TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

The efficacy of anti-CD19 chimeric antigen receptor T-cells (CD19-CAR) against relapsed/refractory B-cell malignancies can be amplified by co-administering them alongside CD20-targeting bispecific...

Scientists have developed a syngeneic mouse model that accurately reflects antitumor activity and adverse effects detected following different types of antibody-based human immunotherapy.

In pursuit of effective treatments for acute myeloid leukemia (AML) and other myeloid malignancies, which have had less success with adoptive cell therapy (ACT) than B-cell malignancies,...

A phase 1 clinical trial, published in the journal Blood Advances, has found the optimal dosing schedule with a tolerable safety profile in patients with relapse/refractory (R/R) acute...

In a recent correspondence letter published in the journal Bone Marrow Transplant, researchers performed a monocentric, retrospective clinical study including adults ( ≥18 years old)...

Researchers from Ehime University in Japan have developed a new bispecific T-cell engager (BiTE), known as briding-BiTE (B-BiTE) which provide two specific binding sites for a tumor antigen of...